sirt2

SIRT2-IN-9 is a selective SRIT2 inhibitor with an IC50 value of 1.3 μM.SIRT2-IN-9 inhibits the proliferation of MCF-7 breast cancer cells.SIRT2-IN-9 can be used for cancer research.

Resveratrol (SRT 501) is a polyphenolic natural product, a plant antitoxin with antioxidant and chemopreventive activities. Resveratrol has a wide range of targets including COX, SIRT, LOC, etc. Resveratrol induces autophagy and apoptosis.

SRT 1720 dihydrochloride is a selective activator of SIRT1 (EC1.5: 0.16 μM) and shows less potent activities on SIRT2 (EC1.5: 37 μM) and SIRT3 (EC1.5: 300 μM).

RK-9123016 is a SIRT2 inhibitor. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.

Dihydrocoumarin (melilotin) is a compound found in Melilotus officinalis. Dihydrocoumarin is a yeast Sir2p inhibitor. Dihydrocoumarin also inhibits human SIRT1 and SIRT2 with IC50s of 208 μM and 295 μM, respectively.

AK-7 is a brain-permeable SIRT2 inhibitor and to characterize its cholesterol-reducing properties in neuronal models with an IC50 of 15.5 μM.

3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor.

SIRT-IN-1 is a potent inhibitor of SIRT1, SIRT2, and SIRT3, with IC50 values of 15, 10, and 33 μM, respectively

Tenovin-3 acts as a p53 activator.

Thiomyristoyl is an effective and selective SIRT2 inhibitor (IC50: 28 nM). It inhibits SIRT1 (IC50: 98 μM) but no effect on SIRT3 even at 200 μM.

AGK2(IC50=3.5 μM) is an effective, and specific SIRT2 inhibitor.

Sirtinol is a selective SIRT1/2 inhibitor (IC50: 131/38 μM).

MIND4-19 is an inhibitor of SIRT2 with antitumor activity.

Sirt2-IN-1 is an inhibitor of sirtuin 2 (IC50 = 163 nM).

WAY-323061 is a SIRT2 inhibitor.

PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC that acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1 Sirt3 (IC50s > 100 μM)[1].

SIRT2-IN-16 (compound 17) is a SIRT2 inhibitor targeted at prostate-specific membrane antigen (PSMA).

SIRT2-IN-17 (compound Z18) is a potent inhibitor of SIRT2, effectively reducing the expression of α-SMA and p-Smad2 3.

SIRT2-IN-10 (Compound 12) is a potent SIRT2 inhibitor (IC50: 1.3 μM) useful for cancer and neurodegenerative disease research.

Sirt2-IN-6 is a potent and selective inhibitor of SIRT2 (IC50: 0.815 μM) and can be used to study cancer.

Sirt2-IN-5, a potent inhibitor of SIRT2, is specifically (2S)-2-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid [exact (1:1) of (2S,4R)-4-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid].

SIRT2-IN-11 (AEM1) is a selective inhibitor of SIRT2 with an inhibitory concentration (IC50) of 18.5 μM. It induces apoptosis in a p53-dependent manner, activates the expression of CDKN1A, PUMA, and NOXA, and enhances the acetylation of p53. This compound is utilized in the study of p53-associated cancers.

Sirt2-IN-7 (compound 22), a selective SIRT2 inhibitor with an IC50 of 178.2 nM and a Ki of 154.3 nM, is employed in cancer research [1].

HSP70 SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].